Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan

Autor:	Hiroki Murayama, Naotsugu Oyama, Tomoko Taniguchi, Yosuke Ishida, Yohei Shinfuku, Takayoshi Sasajima
Rok vydání:	2020
Předmět:	Male medicine.medical_specialty endocrine system diseases Scale (ratio) Postmarketing surveillance 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Japan Product Surveillance Postmarketing medicine Humans Hypoglycemic Agents Pharmacology (medical) Vildagliptin In patient Aged Glycated Hemoglobin Dipeptidyl-Peptidase IV Inhibitors Cardiovascular safety business.industry nutritional and metabolic diseases Type 2 Diabetes Mellitus General Medicine Middle Aged Hypoglycemia Diabetes Mellitus Type 2 Cardiovascular Diseases 030220 oncology & carcinogenesis Emergency medicine Female business medicine.drug
Zdroj:	Expert Opinion on Drug Safety. 19:625-631
ISSN:	1744-764X 1474-0338
DOI:	10.1080/14740338.2020.1740679
Popis:	Objectives: The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin is indicated for type 2 diabetes mellitus (T2DM). However, the long-term safety, effectiveness, and clinical relationship with ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ad27674c3f693b638de9e7da0ffa9cf https://doi.org/10.1080/14740338.2020.1740679 Zobrazit plný text záznamu